Target Name: OGG1
NCBI ID: G4968
Review Report on OGG1 Target / Biomarker Content of Review Report on OGG1 Target / Biomarker
OGG1
Other Name(s): OGH1 | OGG1 variant X1 | N-glycosylase/DNA lyase (isoform X1) | 8-oxoguanine DNA glycosylase | N-glycosylase/DNA lyase isoform 1a | N-glycosylase/DNA lyase isoform 2e | HOGG1 | OGG1_HUMAN | OGG1 variant 1a | AP lyase | N-glycosylase/DNA lyase isoform 2a | N-glycosylase/DNA lyase | 8-hydroxyguanine DNA glycosylase | DNA-(apurinic or apyrimidinic site) lyase | 8-oxoguanine DNA glycosylase, transcript variant X1 | 8-oxoguanine DNA glycosylase, transcript variant 1a | HMMH | OGG1 type 1f | DNA-apurinic or apyrimidinic site lyase | OGG1 variant 2e | OGG1 variant 2a | 8-oxoguanine DNA glycosylase, transcript variant 2a | MUTM | 8-oxoguanine DNA glycosylase, transcript variant 2e

Understanding OGG1: A Potential Drug Target Or Biomarker

OGG1 (Olig2-domain gene 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. OGG1 is a member of the Olig2 gene family, which is known for its role in regulating stem cell proliferation and differentiation.

Studies have shown that OGG1 is involved in the development and progression of various diseases, including cancer. For example, studies have found that high levels of OGG1 expression are associated with poor prognosis in colorectal cancer patients. Additionally, OGG1 has been shown to be involved in the regulation of cell death, which can contribute to the development of neurodegenerative diseases.

In addition to its role in disease progression, OGG1 has also been shown to be a potential biomarker for cancer. For example, studies have found that OGG1 expression is associated with the development of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, OGG1 has been shown to be expressed in the blood vessels of cancer cells, which could be a potential indicator of cancer spread.

Despite its potential as a drug target or biomarker, OGG1 is still not well understood. However, research into the Olig2 gene family has shown that it is involved in the regulation of various cellular processes, including cell adhesion, migration, and angiogenesis. This suggests that OGG1 could be a useful target for drugs that target these processes.

One potential approach to targeting OGG1 is to use drugs that target the Olig2 pathway. This could include drugs that inhibit the activity of Olig2, or drugs that modulate its activity to increase or decrease its function. For example, drugs that inhibit Olig2 could potentially be used to treat cancer by inhibiting its role in cell proliferation and migration. Similarly, drugs that increase Olig2 activity could potentially be used to promote cell death in cancer cells.

Another approach to targeting OGG1 is to use drugs that modulate its expression. This could include drugs that induce OGG1 expression, or drugs that inhibit its degradation. For example, drugs that induce OGG1 expression could potentially be used to increase its levels and improve its function in cancer cells. Similarly, drugs that inhibit OGG1 degradation could potentially be used to increase its levels and improve its function in cancer cells.

While OGG1 is still a relatively well-known gene, its potential as a drug target or biomarker is significant. Further research is needed to fully understand its role in disease progression and its potential as a drug target. However, the study of OGG1 and its role in the Olig2 pathway is an exciting area of research that has the potential to lead to new and effective treatments for a variety of diseases.

Protein Name: 8-oxoguanine DNA Glycosylase

Functions: DNA repair enzyme that incises DNA at 8-oxoG residues. Excises 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine (FAPY) from damaged DNA. Has a beta-lyase activity that nicks DNA 3' to the lesion

The "OGG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OGG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OGN | OGT | OIP5 | OIP5-AS1 | OIT3 | OLA1 | OLA1P1 | OLAH | OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2